Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Summary

This is a randomized, double-masked, vehicle-controlled study of the safety and efficacy of OTX-101 (0.09% cyclosporine nanomicellar solution) in the treatment of keratoconjunctivitis sicca to be conducted at approximately 50 sites.

Timeline

Start

2016-02

Primary completion

2016-11

Completion

2016-12

Drugs

Indications